Table 3.
Clinical parameters and their impact on PFS and OS based on univariate and multivariate analyses
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| PFS | ||||||
| Previous targeted therapya Yes (n = 7) vs. no (n = 43) | 0.650 | 0.273–1.547 | 0.330 | 0.554 | 0.220–1,392 | 0.209 |
| Previous PRRT Yes (n = 13) vs. no (n = 37) | 1.724 | 0.886–3.357 | 0.109 | 1.919 | 0.956–3,855 | 0.067 |
| Resection of primary tumour (n = 23) vs. no resection (n = 27) | 0.969 | 0.541–1.736 | 0.915 | 0.985 | 0.524–1,849 | 0.961 |
| Bone metastases Yes (n = 19) vs. no (n = 31) | 1.144 | 0.625–2.093 | 0.663 | 1.123 | 0.608–2,074 | 0.711 |
| OS from STZ CTx | ||||||
| Previous targeted therapya Yes (n = 7) vs. no (n = 43) | 1.324 | 0.544–3.220 | 0.537 | 1.464 | 0.543–3.946 | 0.452 |
| Previous PRRT Yes (n = 13) vs. no (n = 37) | 1.609 | 0.773–3.353 | 0.204 | 1.429 | 0.581–3.516 | 0.437 |
| Resection of primary tumour (n = 23) vs. no resection (n = 27) | 0.771 | 0.386–1.543 | 0.463 | 0.614 | 0.279–1.352 | 0.226 |
| Bone metastases Yes (n = 19) vs. no (n = 31) | 2.710 | 1.285–5.716 | 0.009 | 2.637 | 1.205–5.772 | 0.015 |
All p-values have been specified as italicized values and all values showing statistical significance were highlighted using bold characters
aEverolimus and/ or sunitinib